Improving the quality of life in Arizona to benefit future generations.
Arizona's technology sector scored a long-awaited victory at the Legislature with last week's passage of a bill that would entice angel investors to buy in to early-stage technology companies in the state. The angel-investment bill, now on the governor's desk, ends a string of legislative defeats over recent years to spur seed capital.
Coordinating an event such as the recent Arizona Bio Expo on nonbillable time is no small feat. But that degree of work comes naturally to Jon McGarity, current chairman of the Arizona Bioindustry Association. McGarity says the ABA is betting on a bright future for Arizona's bioindustry, and he is doing the legwork to get it there.
A new report on Arizona health and biosciences recommends bold measures for the state to "leapfrog" competitor states and regions in order to more fully participate in the biosciences economy.
Arizona's annual conference to showcase its top bioscience research and industry practices opened on March 29 with the reading of a gubernatorial proclamation to honor the day as "Arizona Bioindustry Day."
On the second day of spring, Arizona leaders, renowned scientists, and members of the local press flocked to the grand opening of the Translational Genomics Research Institute building. Located east of the Arizona Center, the building is both the physical and symbolic anchor of a biosciences cluster cropping up in downtown Phoenix.
The Arizona Board of Regents approved a land trade last week that will allow University of Arizona officials to move ahead on plans for a biotechnology park on Tucson's South Side. Approval of the land exchange is the latest step in the construction of the Critical Path Institute (C-Path), the new FDA-affiliated drug development institute that will anchor the biotechnology park near the university.
The traditional 'topping-out' ceremony of the upcoming BIO5 building at UA was held in early March before a crowd of university officials, researchers and local press.
This past fall Vicki Chandler, the newly appointed director of the Institute for Biomedical Science and Biotechnology (IBSB) at the University of Arizona, rescued the up-and-coming research center from its own cumbersome name and rechristened it BIO5, a decidedly catchier moniker. But a name change isn't nearly all that Chandler has accomplished since officially taking the reins of BIO5 last July.